Phage Therapy Starts Realizing Its Long-Deferred Potential

Interagency Coordination Group on Antimicrobial Resistance. No time to wait: Securing the future from drug-resistant infections—Report to the secretary-general of the United Nations. World Organization for Animal Health. https://www.woah.org/fileadmin/Home/eng/Media_Center/docs/pdf/IACG2019/IACG_final_report_EN.pdf. Published April 2019. Accessed July 2022.

Kumuran D , Taha M , Yi Q , et al. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front. Microbiol. , 2018; 9: 127. DOI: 10.3389/fmicb.2018.00127

Hadden WJ , Ibrahim M , Taha M , et al. 2021 Frank Stinchfield Award: A novel cemented hip hemiarthroplasty infection model with real-time in vivo imaging in rats. Bone Joint J. , 2021; 103-B (7 Suppl. B): 9–16. DOI: 10.1302/0301-620X.103B7.BJJ-2020-2435.R1.

Jault P , Leclerc T , Jennes S , et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. , 2019; 19: 35–45. DOI: 10.1016/S1473-3099(18)30482-1.

Djebara S , Maussen C , De Vos D , et al. Processing phage therapy requests in a Brussels military hospital: Lessons identified. Viruses , 2019; 11: 3. DOI: 10.3390/ v11030265.

Cass J , Barnard A , Fairhead H . Engineered bacteriophage as a delivery vehicle for antibacterial protein, SASP. Pharmaceuticals (Basel) , 2021; 14: 10. DOI: 10.3390/ph14101038.

CYstic Fibrosis BacterioPHage Study at Yale (CYPHY). ClinicalTrials.gov Identifier: NCT04684641.

Locus Biosciences. Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product. Published September 30, 2020. Accessed June 22, 2022.